【作者】 房高丽；

【导师】 李桂芝；

【作者基本信息】 吉林大学 ， 耳鼻咽喉科学， 2005， 硕士

【摘要】 目的:通过检测喉鳞状细胞癌患者血清中及喉鳞状细胞癌组织中IL-18 的表达,探讨IL-18 与喉鳞状细胞癌的相关性。方法:应用ELISA 法检测30 例喉鳞状细胞癌患者和15 例正常对照血清中IL-18 的表达;采用免疫组织化学S-P 法检测39 例喉鳞状细胞癌组织、21 例声带不典型增生组织及10 例正常喉组织中IL-18 蛋白的表达。并结合临床参数探讨其与喉鳞状细胞癌的相关性。结果:喉鳞癌患者血清中平均IL-18 含量为明显高于对照组(P<0.05),且与临床进展密切相关;10 例正常喉组织有较强的IL-18 蛋白的表达,正常喉组织、喉粘膜不典型增生、喉癌组织中IL-18 阳性表达率分别为100%、81%、59%,喉癌与声带不典型增生、喉癌与正常喉粘膜IL-18 的表达差异具有统计学意义(均P<0.05);声带不典型增生组织中IL-18 的表达比正常喉粘膜有下降趋势,但无统计学意义(P>0.05)。IL-18 蛋白阴性喉癌颈部淋巴结转移率为;IL-18 蛋白阳性喉癌颈部淋巴结转移率为,两者之间差异有统计学意义。晚期、低分化、伴颈部淋巴结转移的喉癌组织中IL-18 阳性表达率显著低于早期、高分化、无颈部淋巴结转移的喉癌组织,各组间差异均具有统计学意义(P<0.05)。而且,IL-18 蛋白在喉癌组织中的表达降低与不良的临床预后呈正相关。结论:喉鳞状细胞癌患者血清中IL-18 蛋白的表达明显升高,与临床进展密切相关;IL-18 蛋白在喉鳞状细胞组织中表达下降,晚期、低分化、伴颈部更多还原

【Abstract】 Objective: Interleukin(IL)-18 is a potent immunomodulatorycytokine promoting Th-1 and cytotoxic immune responses throughinterferon(IFN)-γinduction. The aim of this study was to investigatethe production of IL-18 in laryngeal squamous cell carcinomas(LSCC).Methods: Serum IL-18 level were determined in patients with LSCC,and the relationship with clinicopathologic factors was investigated.Peripheral blood samples were obtained from 15 healthy volunteers andfrom 30 patients with LSCC before curative surgery. IL-18 level wasdetermined in each serum sample by enzyme-linked immunosorbent assay(ELISA). Immunohistochemical analysis was performed on tumor specimensfrom 39 patients with primary LSCC, 21 cases of atypical hyperplasia ofvocal fold and 10 healthy controls.Results: Mean serum IL-18 level was significantly higher in patientswith LSCC compared with healthy volunteers (P< 0.05) and mean serum IL-18level increased in patients as the pathologic stage progressed. Theexpression of IL-18 protein in LSCC tissue specimens was significantlylower compared with healthy volunteers (P< 0.05) and correlated withworse prognosis.Conclusions: In patients with LSCC, increasing IL-18 levelcorrelated with tumor growth and progression. Tissue IL-18 level mightcorrelate with a certain depth of invasion and might be useful tumormarkers in patients with LSCC.更多还原